4D Molecular Therapeutics Inc
NASDAQ: FDMT · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
4D Molecular Therapeutics Inc (FDMT) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for FDMT.
Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.
FDMT historical valuation range
Where current P/E sits in FDMT's own 5Y range.
FDMT intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Standard discounted cash flow models produce unreliable output for unprofitable or near-breakeven companies. Revenue-based multiples such as P/S and EV/Sales, combined with the historical valuation position above, give a more reliable read for this stock.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
FDMT valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
P/S Ratio — History
Current: 5.12x
Is FDMT overvalued in 2026?
4D Molecular Therapeutics Inc (FDMT) currently trades at $10.34 per share with a market capitalization of $451,667,000.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 38/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
FDMT currently has no meaningful P/E ratio, which typically signals that the company is unprofitable, near breakeven, or emerging from a loss-making period. With a P/S ratio of 5.1x, the market is valuing the company primarily on its revenue rather than its earnings.
A standard DCF model does not produce reliable output for FDMT under current conditions. For unprofitable or near-breakeven companies, revenue-based multiples such as EV/Sales and historical P/S percentile are more informative than intrinsic value calculations.
Financial quality is a concern. The Piotroski F-Score of 3/9 flags weakening fundamentals that deserve closer scrutiny before the valuation case can be fully trusted.
Bottom line: FDMT appears richly valued on our framework, with a Smart Value Score of 38/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.
Frequently asked questions
Is FDMT overvalued?
FDMT scores 38/100 on our Smart Value Score (Grade D), a weak overall profile. A standard DCF is unreliable here given the profitability profile, so valuation leans on revenue-based measures like EV/Sales and the P/S percentile below.
What is FDMT's fair value?
A standard DCF is unreliable for FDMT given its current profitability profile. Revenue-based approaches like EV/Sales or the historical P/S percentile are more informative for this stock.
What P/E ratio does FDMT trade at?
FDMT does not have a meaningful P/E right now, usually a sign of unprofitability or an earnings transition. For unprofitable growth names, price-to-sales is the more useful gauge.
Is FDMT a buy based on valuation?
Our Smart Value rating for FDMT is Sell, from a Smart Value Score of 38/100 that blends growth, quality, and valuation. The profile skews cautious, and a better price or clearer operating improvement would strengthen the case. This is research to inform your decision, not personalized financial advice.
How does FDMT's valuation compare to its history?
There is not enough historical valuation data yet for a confident percentile read on FDMT.
What is FDMT's Smart Value Score?
FDMT's Smart Value Score is 38/100. It is a proprietary WallStSmart metric blending growth quality, financial health, and valuation into a single 0-100 read, and scores above 75 are rare, signaling strong multi-factor alignment.